Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Apeiron Biologics gets a EUR 25 million loan from EIB

Apeiron CEO H. Loibner © Apeiron Biologics

The funds are designed to help the company develop new pharmaceutical products for the treatment of cancer, especially rare types affecting children. The financing for Apeiron was made possible by the “European Fund for Strategic Investments” (EFSI).

Apeiron was founded in 2003 by the geneticist Josef Penninger, the scientific director of the Institute for Molecular Biology (IMBA) in Vienna. In May 2017, the European Commission granted market approval for a therapy focusing on immunotherapy of neuroblastoma. The therapy should increase the survival and chances of recovery for the serious cancer neuroblastoma which affects children at an early age. It is a rare cancer, but is responsible for up to 10% of solid tumors in childhood, affecting about 1,200 children in the EU and USA every year.  

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Medica in Dusseldorf

    12. - 15.11.2018, Dusseldorf, Germany

Austria Map

Find the perfect location for your company

Inspite of higher labor costs, the productivity of Siemens Villach is comparable to other Siemens susidiaries in Japan or the USA.

Siemens Austria

Logo
More testimonials

news from the business location Austria

PwC study: Five publicly-listed Austrian companies among the top 1,000 in R&D

The 1,000 largest publicly listed companies have never invested as much in research and development as they did in 2018.

Where Live the Data

In the age of digitalization, success depends on one simple question: “Where and how do you process your data?” In our data-driven world, the decisive issue in ensuring that your company remains part of the value chain is how you handle your data. Here you will find out why different types of data require different strategies, and what you can learn from the plans of leading decision makers.

More news All blog posts